A novel mobile app and population management system to manage rheumatoid arthritis flares: Protocol for a randomized controlled trial

Penny Wang, Dee Luo, Fengxin Lu, Josephine S. Elias, Adam B. Landman, Kaleb D Michaud, Yvonne C. Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Rheumatoid arthritis flares have a profound effect on patients, causing pain and disability. However, flares often occur between regularly scheduled health care provider visits and are, therefore, difficult to monitor and manage. We sought to develop a mobile phone app combined with a population management system to help track RA flares between visits. Objective: The objective of this study is to implement the mobile app plus the population management system to monitor rheumatoid arthritis disease activity between scheduled health care provider visits over a period of 6 months. Methods: This is a randomized controlled trial that lasts for 6 months for each participant. We aim to recruit 190 patients, randomized 50:50 to the intervention group versus the control group. The intervention group will be assigned the mobile app and be prompted to answer daily questionnaires sent to their mobile devices. Both groups will be assigned a population manager, who will communicate with the participants via telephone at 6 weeks and 18 weeks. The population manager will also communicate with the participants in the intervention group if their responses indicate a sustained increase in rheumatoid arthritis disease activity. To assess patient satisfaction, the primary outcomes will be scores on the Treatment Satisfaction Questionnaire for Medication as well as the Perceived Efficacy in Patient-Physician Interactions questionnaire at 6 months. To determine the effect of the mobile app on rheumatoid arthritis disease activity, the primary outcome will be the Clinical Disease Activity Index at 6 months. Results: The trial started in November 2016, and an estimated 2.5 years will be necessary to complete the study. Study results are expected to be published by the end of 2019. Conclusions: The completion of this study will provide important data regarding the following: (1) the assessment of validated outcome measures to assess rheumatoid arthritis disease activity with a mobile app between routinely scheduled health care provider visits, (2) patient engagement in monitoring their condition, and (3) communication between patients and health care providers through the population management system. Trial Registration: ClinicalTrials.gov NCT02822521, http://clinicaltrials.gov/ct2/show/NCT02822521 (Archived by WebCite at http://www.webcitation.org/6xed3kGPd).

Original languageEnglish (US)
Article numbere84
JournalJournal of Medical Internet Research
Volume20
Issue number4
DOIs
StatePublished - Apr 2018

Fingerprint

Mobile Applications
Rheumatoid Arthritis
Randomized Controlled Trials
Health Personnel
Population
Patient Participation
Cell Phones
Patient Satisfaction
Telephone
Patient Care
Communication
Outcome Assessment (Health Care)
Physicians
Pain
Equipment and Supplies
Control Groups
Surveys and Questionnaires

Keywords

  • Arthritis
  • Mobile applications
  • Rheumatoid
  • Symptom flare up
  • Telemedicine

ASJC Scopus subject areas

  • Health Informatics

Cite this

A novel mobile app and population management system to manage rheumatoid arthritis flares : Protocol for a randomized controlled trial. / Wang, Penny; Luo, Dee; Lu, Fengxin; Elias, Josephine S.; Landman, Adam B.; Michaud, Kaleb D; Lee, Yvonne C.

In: Journal of Medical Internet Research, Vol. 20, No. 4, e84, 04.2018.

Research output: Contribution to journalArticle

Wang, Penny ; Luo, Dee ; Lu, Fengxin ; Elias, Josephine S. ; Landman, Adam B. ; Michaud, Kaleb D ; Lee, Yvonne C. / A novel mobile app and population management system to manage rheumatoid arthritis flares : Protocol for a randomized controlled trial. In: Journal of Medical Internet Research. 2018 ; Vol. 20, No. 4.
@article{87d4a12426c34bfd81ad659ac4628ada,
title = "A novel mobile app and population management system to manage rheumatoid arthritis flares: Protocol for a randomized controlled trial",
abstract = "Background: Rheumatoid arthritis flares have a profound effect on patients, causing pain and disability. However, flares often occur between regularly scheduled health care provider visits and are, therefore, difficult to monitor and manage. We sought to develop a mobile phone app combined with a population management system to help track RA flares between visits. Objective: The objective of this study is to implement the mobile app plus the population management system to monitor rheumatoid arthritis disease activity between scheduled health care provider visits over a period of 6 months. Methods: This is a randomized controlled trial that lasts for 6 months for each participant. We aim to recruit 190 patients, randomized 50:50 to the intervention group versus the control group. The intervention group will be assigned the mobile app and be prompted to answer daily questionnaires sent to their mobile devices. Both groups will be assigned a population manager, who will communicate with the participants via telephone at 6 weeks and 18 weeks. The population manager will also communicate with the participants in the intervention group if their responses indicate a sustained increase in rheumatoid arthritis disease activity. To assess patient satisfaction, the primary outcomes will be scores on the Treatment Satisfaction Questionnaire for Medication as well as the Perceived Efficacy in Patient-Physician Interactions questionnaire at 6 months. To determine the effect of the mobile app on rheumatoid arthritis disease activity, the primary outcome will be the Clinical Disease Activity Index at 6 months. Results: The trial started in November 2016, and an estimated 2.5 years will be necessary to complete the study. Study results are expected to be published by the end of 2019. Conclusions: The completion of this study will provide important data regarding the following: (1) the assessment of validated outcome measures to assess rheumatoid arthritis disease activity with a mobile app between routinely scheduled health care provider visits, (2) patient engagement in monitoring their condition, and (3) communication between patients and health care providers through the population management system. Trial Registration: ClinicalTrials.gov NCT02822521, http://clinicaltrials.gov/ct2/show/NCT02822521 (Archived by WebCite at http://www.webcitation.org/6xed3kGPd).",
keywords = "Arthritis, Mobile applications, Rheumatoid, Symptom flare up, Telemedicine",
author = "Penny Wang and Dee Luo and Fengxin Lu and Elias, {Josephine S.} and Landman, {Adam B.} and Michaud, {Kaleb D} and Lee, {Yvonne C.}",
year = "2018",
month = "4",
doi = "10.2196/resprot.8771",
language = "English (US)",
volume = "20",
journal = "Journal of Medical Internet Research",
issn = "1439-4456",
publisher = "Journal of medical Internet Research",
number = "4",

}

TY - JOUR

T1 - A novel mobile app and population management system to manage rheumatoid arthritis flares

T2 - Protocol for a randomized controlled trial

AU - Wang, Penny

AU - Luo, Dee

AU - Lu, Fengxin

AU - Elias, Josephine S.

AU - Landman, Adam B.

AU - Michaud, Kaleb D

AU - Lee, Yvonne C.

PY - 2018/4

Y1 - 2018/4

N2 - Background: Rheumatoid arthritis flares have a profound effect on patients, causing pain and disability. However, flares often occur between regularly scheduled health care provider visits and are, therefore, difficult to monitor and manage. We sought to develop a mobile phone app combined with a population management system to help track RA flares between visits. Objective: The objective of this study is to implement the mobile app plus the population management system to monitor rheumatoid arthritis disease activity between scheduled health care provider visits over a period of 6 months. Methods: This is a randomized controlled trial that lasts for 6 months for each participant. We aim to recruit 190 patients, randomized 50:50 to the intervention group versus the control group. The intervention group will be assigned the mobile app and be prompted to answer daily questionnaires sent to their mobile devices. Both groups will be assigned a population manager, who will communicate with the participants via telephone at 6 weeks and 18 weeks. The population manager will also communicate with the participants in the intervention group if their responses indicate a sustained increase in rheumatoid arthritis disease activity. To assess patient satisfaction, the primary outcomes will be scores on the Treatment Satisfaction Questionnaire for Medication as well as the Perceived Efficacy in Patient-Physician Interactions questionnaire at 6 months. To determine the effect of the mobile app on rheumatoid arthritis disease activity, the primary outcome will be the Clinical Disease Activity Index at 6 months. Results: The trial started in November 2016, and an estimated 2.5 years will be necessary to complete the study. Study results are expected to be published by the end of 2019. Conclusions: The completion of this study will provide important data regarding the following: (1) the assessment of validated outcome measures to assess rheumatoid arthritis disease activity with a mobile app between routinely scheduled health care provider visits, (2) patient engagement in monitoring their condition, and (3) communication between patients and health care providers through the population management system. Trial Registration: ClinicalTrials.gov NCT02822521, http://clinicaltrials.gov/ct2/show/NCT02822521 (Archived by WebCite at http://www.webcitation.org/6xed3kGPd).

AB - Background: Rheumatoid arthritis flares have a profound effect on patients, causing pain and disability. However, flares often occur between regularly scheduled health care provider visits and are, therefore, difficult to monitor and manage. We sought to develop a mobile phone app combined with a population management system to help track RA flares between visits. Objective: The objective of this study is to implement the mobile app plus the population management system to monitor rheumatoid arthritis disease activity between scheduled health care provider visits over a period of 6 months. Methods: This is a randomized controlled trial that lasts for 6 months for each participant. We aim to recruit 190 patients, randomized 50:50 to the intervention group versus the control group. The intervention group will be assigned the mobile app and be prompted to answer daily questionnaires sent to their mobile devices. Both groups will be assigned a population manager, who will communicate with the participants via telephone at 6 weeks and 18 weeks. The population manager will also communicate with the participants in the intervention group if their responses indicate a sustained increase in rheumatoid arthritis disease activity. To assess patient satisfaction, the primary outcomes will be scores on the Treatment Satisfaction Questionnaire for Medication as well as the Perceived Efficacy in Patient-Physician Interactions questionnaire at 6 months. To determine the effect of the mobile app on rheumatoid arthritis disease activity, the primary outcome will be the Clinical Disease Activity Index at 6 months. Results: The trial started in November 2016, and an estimated 2.5 years will be necessary to complete the study. Study results are expected to be published by the end of 2019. Conclusions: The completion of this study will provide important data regarding the following: (1) the assessment of validated outcome measures to assess rheumatoid arthritis disease activity with a mobile app between routinely scheduled health care provider visits, (2) patient engagement in monitoring their condition, and (3) communication between patients and health care providers through the population management system. Trial Registration: ClinicalTrials.gov NCT02822521, http://clinicaltrials.gov/ct2/show/NCT02822521 (Archived by WebCite at http://www.webcitation.org/6xed3kGPd).

KW - Arthritis

KW - Mobile applications

KW - Rheumatoid

KW - Symptom flare up

KW - Telemedicine

UR - http://www.scopus.com/inward/record.url?scp=85047734984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047734984&partnerID=8YFLogxK

U2 - 10.2196/resprot.8771

DO - 10.2196/resprot.8771

M3 - Article

C2 - 29643053

AN - SCOPUS:85047734984

VL - 20

JO - Journal of Medical Internet Research

JF - Journal of Medical Internet Research

SN - 1439-4456

IS - 4

M1 - e84

ER -